[
    [
        {
            "time": "",
            "original_text": "【权益变动】泰格医药(03347-HK)获摩根大通增持27.3万股",
            "features": {
                "keywords": [
                    "泰格医药",
                    "摩根大通",
                    "增持"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【权益变动】泰格医药(03347-HK)获摩根大通增持27.3万股",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业日报：美国礼来暂停新冠抗体药物后期试验",
            "features": {
                "keywords": [
                    "医药生物",
                    "礼来",
                    "新冠抗体药物",
                    "暂停试验"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物行业日报：美国礼来暂停新冠抗体药物后期试验",
                "Correlation": 5,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "泰格医药：间接持股公司普蕊斯辅导备案登记已获受理",
            "features": {
                "keywords": [
                    "泰格医药",
                    "普蕊斯",
                    "辅导备案",
                    "受理"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "泰格医药：间接持股公司普蕊斯辅导备案登记已获受理",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]